-
M.
Charokopou,
P.
McEwan,
S.
Lister,
L.
Callan,
K.
Bergenheim,
K.
Tolley,
R.
Postema,
R.
Townsend,
M.
Roudaut
(2015)
The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus
Diabetic Medicine, 32
-
(2015)
[Cost-effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type-2 diabetes mellitus in Spain]
, 47
-
A.
Kansal,
O.
Reifsnider,
Joseph
Lee,
K.
Fahrbach,
P.
Gandhi,
E.
Pfarr,
A.
Ustyugova
(2018)
Cost-Effectiveness Analysis of Empagliflozin Compared with Canagliflozin or Standard of Care (SoC) in Patients with T2DM and Established Cardiovascular (CV) Disease
Diabetes
-
M.
Charokopou,
H.
Vioix,
L.
Eddowes,
M.
Griffiths,
B.
Verheggen,
Z.
Gabriel,
K.
Tolley
(2014)
Cost-Effectiveness of Dapagliflozin Compared To Dpp-4 Inhibitors as Triple Therapy In Combination With Metformin and A Sulphonylurea In The Treatment Of Type 2 Diabetes Mellitus From A Uk Health Care Perspective.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17 7
-
Ping
Zhang,
M.
Laxy,
T.
Hoerger,
Inna
Cintina,
Wenya
Yang
(2018)
Economic Costs of Diabetes in the U.S. in 2017
Diabetes Care, 41
-
E.
Oksuz,
S.
Malhan,
E.
Kamaci,
B.
Urganci,
E.
Tetik,
A.
Temizhan,
R.
Ersoy,
Y.
Balbay
(2017)
Cost-Effectiveness of Empagliflozin (Jardiance®) In The Treatment of Patients With Type 2 Diabetes Mellitus (T2DM) In Turkey Based Empa-Reg Outcome Data
Value in Health, 20
-
T.
Bacon,
M.
Willis,
P.
Johansen,
C.
Neslusan,
S.
Nuhoho,
M.
Worbes-Cerezo
(2014)
The Cost-Effectiveness of Canagliflozin Verse Insulin-Secretagogues (Sulphonylureas) or Insulin In Patients With Type 2 Diabetes Mellitus (T2dm) As An Add-On To Metformin In Ireland.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17 7
-
H.
Haalen,
M.
Pompen,
K.
Bergenheim,
P.
McEwan,
R.
Townsend,
M.
Roudaut
(2014)
Cost Effectiveness of Adding Dapagliflozin to Insulin for the Treatment of Type 2 Diabetes Mellitus in the Netherlands
Clinical Drug Investigation, 34
-
B.
Zinman,
C.
Wanner,
J.
Lachin,
D.
Fitchett,
E.
Bluhmki,
S.
Hantel,
M.
Mattheus,
T.
Devins,
O.
Johansen,
H.
Woerle,
U.
Broedl,
S.
Inzucchi
(2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
The New England journal of medicine, 373 22
-
A.
Troelsgaard,
A.
Pitcher,
D.
Granados,
M.
Hemels,
A.
Lloyd
(2014)
The Cost-Effectiveness of Canagliflozin Compared With Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Metformin and Sulfonylurea In France.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17 7
-
R.
Aguiar-Ibáñez,
R.
Palencia,
P.
Kandaswamy,
L.
Li
(2014)
Cost-Effectiveness of Empagliflozin (Jardiance®) 10 Mg And 25 Mg Administered As An Add-On To Metformin And Sulfonilurea (Met+Su) Compared To Other Sodium-Glucose Co-Transporter 2 Inhibitors (Sglt2is) in Patients with Type 2 Diabetes Mellitus (T2dm) In The Uk.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17 7
-
Uk-Prospective-Diabetes-Study-Group
(1998)
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
The Lancet, 352
-
M.
Charokopou,
H.
Vioix,
B.
Verheggen,
L.
Eddowes,
M.
Griffiths,
Z.
Gabriel,
K.
Tolley,
D.
Franks
(2014)
Cost-Effectiveness of Dapagliflozin Versus Dpp-4 Inhibitors as Monotherapy in the Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17 7
-
A.
Serna,
P.
Mezquita‐Raya,
G.
Vega-Hernandez,
R.
Wojcik,
M.
Schlueter
(2016)
Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type-2 Diabetes Mellitus in Spain: A Cost-Effectiveness Analysis
Value in Health, 19
-
C.
Bommer,
Vera
Sagalova,
E.
Heesemann,
J.
Manne-Goehler,
R.
Atun,
T.
Bärnighausen,
J.
Davies,
S.
Vollmer
(2018)
Global Economic Burden of Diabetes in Adults: Projections From 2015 to 2030
Diabetes Care, 41
-
M.
Charokopou,
H.
Vioix,
B.
Verheggen,
D.
Maddocks,
T.
Bratt,
D.
Franks
(2014)
Economic Assessment of Delaying Insulin Treatment Through The Use of Newer Anti-Diabetic Agents, Dapagliflozin (Forxiga®) And Exenatide (Bydureon®), Both As Add-On To Metformin; A Cost-Effectiveness Analysis From A Uk Nhs Perspective.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17 7
-
A.
Garber,
M.
Abrahamson,
J.
Barzilay,
L.
Blonde,
Z.
Bloomgarden,
Michael
Bush,
S.
Dagogo-Jack,
R.
DeFronzo,
D.
Einhorn,
V.
Fonseca,
J.
Garber,
W.
Garvey,
G.
Grunberger,
Y.
Handelsman,
I.
Hirsch,
P.
Jellinger,
J.
McGill,
J.
Mechanick,
P.
Rosenblit,
G.
Umpierrez
(2018)
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 24 1
-
T.
Bacon,
M.
Willis,
P.
Johansen,
C.
Neslusan,
S.
Nuhoho,
M.
Worbes-Cerezo
(2014)
The Cost-Effectiveness Of Canagliflozin Verse Liraglutide In Patients With Type 2 Diabetes (T2dm) Failing To Achieve Glycaemic Control On Metformin Monotherapy In Ireland.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17 7
-
B.
Neal,
V.
Perkovic,
K.
Mahaffey,
D.
Zeeuw,
G.
Fulcher,
N.
Erondu,
Wayne
Shaw,
G.
Law,
Mehul
Desai,
D.
Matthews
(2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
The New England Journal of Medicine, 377
-
L.
Henkhaus,
J.
Hay
(2016)
COST EFFECTIVENESS OF EMPAGLIFLOZIN/LINAGLIPTIN AS 2ND-LINE THERAPY FOR ADULTS WITH TYPE 2 DIABETES
Value in Health, 19
-
U.
Sabale,
M.
Ekman,
O.
Granström,
K.
Bergenheim,
P.
McEwan
(2015)
Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries.
Primary care diabetes, 9 1
-
E.
Nguyen,
C.
Coleman,
Suresh
Nair,
E.
Weeda
(2018)
Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk.
Journal of diabetes and its complications, 32 2
-
M.
Abdul-Ghani,
S.
Prato,
R.
Chilton,
R.
DeFronzo
(2016)
SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
, 39
-
S.
Gu,
Y.
Mu,
S.
Zhai,
Yuhang
Zeng,
X.
Zhen,
Hengjin
Dong
(2016)
Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China
PLoS ONE, 11
-
(1998)
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).
, 352
-
(2018)
American Diabetes Association. Cardiovascular disease and risk management: standards of medical care in diabetes-2018
, 41
-
G.
Vega-Hernandez,
R.
Wojcik,
M.
Schlueter
(2017)
Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK
Diabetes Therapy, 8
-
Cost-effectiveness study of EMPA in high cardio-vascular risk individuals with T2DM
-
M.
Charokopou,
H.
Vioix,
B.
Verheggen,
S.
Dillon,
D.
Franks
(2014)
Dapagliflozin (Forxiga®) Versus Glipizide As Add-On Therapies In Type 2 Diabetes Mellitus (T2dm); An Update of The Cost-Effectiveness Based On Long-Term Clinical Evidence From Uk Nhs Perspective.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17 7
-
S.
Inzucchi,
R.
Bergenstal,
J.
Buse,
M.
Diamant,
E.
Ferrannini,
M.
Nauck,
A.
Peters,
A.
Tsapas,
R.
Wender,
D.
Matthews
(2014)
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Diabetes Care, 38
-
D.
Pawlik,
R.
Wójcik,
A.
Zawodnik,
M.
Kaczor
(2017)
Cost-Effectiveness of Empagliflozin In Patients With Type 2 Diabetes Mellitus At High Cardiovascular Risk In Poland
Value in Health, 20
-
M.
Schroeder,
P.
Johansen,
M.
Willis,
C.
Neslusan
(2015)
The Cost-Effectiveness of Canagliflozin (CANA) Versus Dapagliflozin (Dapa) 10mg and Empagliflozin (EMPA) 25mg in Patients with Type 2 Diabetes Mellitus (T2DM) as Monotherapy in the United Kingdom.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 18 7
-
S.
Palmer,
D.
Mavridis,
A.
Nicolucci,
David
Johnson,
M.
Tonelli,
J.
Craig,
Jasjot
Maggo,
Vanessa
Gray,
G.
Berardis,
M.
Ruospo,
P.
Natale,
V.
Saglimbene,
S.
Badve,
Yeoungjee
Cho,
Annie-Claire
Nadeau-Fredette,
M.
Burke,
L.
Faruque,
Anita
Lloyd,
Nasreen
Ahmad,
Yuanchen
Liu,
Sophanny
Tiv,
N.
Wiebe,
G.
Strippoli
(2016)
Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis.
JAMA, 316 3
-
Wholesale acquisition cost
-
S.
Marso,
S.
Bain,
A.
Consoli,
F.
Eliaschewitz,
E.
Jódar,
Lawrence
Leiter,
I.
Lingvay,
J.
Rosenstock,
J.
Seufert,
M.
Warren,
V.
Woo,
O.
Hansen,
A.
Holst,
Jonas
Pettersson,
T.
Vilsbøll
(2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
The New England journal of medicine, 375 19
-
D.
Szmurło,
R.
Drzal,
R.
Plisko,
A.
Schubert,
I.
Skrzekowska-Baran
(2014)
Cost Effectiveness Evaluation of Canagliflozin in Combination with Metformin and Sulfonylurea in Comparison To Nph Insulin in the Treatment of Type 2 Diabetes Mellitus In Poland.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17 7
-
Anushka
Patel
(2007)
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial
The Lancet, 370
-
Eduardo
Paniagua,
P.
Escribano,
José
Rodríguez,
Francisco
Escobar,
Lourdes
Nicolás,
J.
Sánchez-Covisa,
M.
Brosa
(2014)
Análisis de coste-efectividad de dapagliflozina en comparación con los inhibidores de la DPP4 y otros antidiabéticos orales en el tratamiento de la diabetes mellitus tipo 2 en España☆
Atencion Primaria, 47
-
S.
Sabapathy,
C.
Neslusan,
K.
Yoong,
A.
Teschemaker,
P.
Johansen,
M.
Willis
(2016)
Cost-effectiveness of Canagliflozin versus Sitagliptin When Added to Metformin and Sulfonylurea in Type 2 Diabetes in Canada.
Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharamcologie clinique, 23 2
-
S.
Hill,
A.
Mitchell,
D.
Henry
(2000)
Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme.
JAMA, 283 16
-
Vittorio
Basevi
(2011)
Standards of Medical Care in Diabetes—2012
Diabetes Care, 35
-
D.
Szmurło,
R.
Drzal,
R.
Plisko,
A.
Schubert,
I.
Skrzekowska-Baran
(2014)
Cost Effectiveness Evaluation of Canagliflozin In Combination With Metformin in the Treatment Of Type 2 Diabetes Mellitus In Poland.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17 7
-
P.
Odegard,
S.
Gray
(2008)
Barriers to Medication Adherence in Poorly Controlled Diabetes Mellitus
The Diabetes Educator, 34
-
R.
Holman,
S.
Paul,
M.
Bethel,
D.
Matthews,
H.
Andrew,
W.
Neil
(2008)
10-year follow-up of intensive glucose control in type 2 diabetes.
The New England journal of medicine, 359 15
-
M.
Charokopou,
P.
McEwan,
S.
Lister,
L.
Callan,
K.
Bergenheim,
K.
Tolley,
R.
Postema,
R.
Townsend,
M.
Roudaut
(2015)
Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective
BMC Health Services Research, 15
-
G.
Gourzoulidis,
C.
Tzanetakos,
I.
Ioannidis,
A.
Tsapas,
G.
Kourlaba,
G.
Papageorgiou,
N.
Maniadakis
(2017)
Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece
Clinical Drug Investigation, 38
-
C.
Neslusan,
A.
Teschemaker,
M.
Willis,
P.
Johansen,
L.
Vo
(2018)
Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States
Diabetes Therapy, 9
-
Cost-effectiveness study of CANA on background of MET
-
J.
Sánchez-Covisa,
M.
Capel,
R.
Schmidt,
M.
Charokopou,
B.
Verheggen
(2014)
The Cost-Effectiveness of Dapagliflozin In Combination With Insulin for the Treatment of Type 2 Diabetes Mellitus (T2dm) In Spain.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17 7
-
Abhiroop
Chakravarty,
Mohini
Rastogi,
Praveen
Dhankhar,
K.
Bell
(2018)
Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting
Journal of Medical Economics, 21
-
I.
Daacke,
P.
Kandaswamy,
A.
Tebboth,
A.
Kansal,
O.
Reifsnider
(2016)
Cost-Effectiveness of Empagliflozin (Jardiance) in the Treatment of Patients with Type 2 Diabetes Mellitus (T2DM) in the UK Based on Empa-Reg Outcome Data
Value in Health, 19
-
S.
Inzucchi,
R.
Bergenstal,
J.
Buse,
M.
Diamant,
E.
Ferrannini,
M.
Nauck,
A.
Peters,
A.
Tsapas,
R.
Wender,
D.
Matthews
(2012)
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Diabetes Care, 35
-
C.
Neslusan,
A.
Teschemaker,
P.
Johansen,
M.
Willis,
A.
Valencia-Mendoza,
A.
Puig
(2015)
Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus in Mexico.
Value in health regional issues, 8
-
L.
Pititto,
C.
Neslusan,
A.
Teschemaker,
P.
Johansen,
M.
Willis,
E.
Asano,
A.
Puig
(2015)
Cost-Effectiveness of Canagliflozin (Cana) Versus Sitagliptin (Sita) As Add-On To Metformin Plus Sulfonylurea In Patients With Type 2 Diabetes Mellitus (T2dm) In Brazil.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 18 7
-
H.
Shao,
S.
Zhai,
D.
Zou,
M.
Mir,
N.
Zawadzki,
Q.
Shi,
Shuqian
Liu,
Lizheng
Shi
(2017)
Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus
Current Medical Research and Opinion, 33
-
S.
Iannazzo,
E.
Mannucci,
O.
Reifsnider,
A.
Maggioni
(2017)
Cost-Effectiveness Analysis of Empagliflozin In The Treatment Of T2d With Previous Cardiovascular Disease In Italy
Value in Health, 20
-
Timothy
Dall,
P.
Nikolov,
P.
Hogan
(2003)
Economic Costs of Diabetes in the U.S. in 2002
-
Juan
Frias
(2018)
Introduction: Standards of Medical Care in Diabetes—2019
Diabetes Care, 42
-
R.
Aguiar-Ibáñez,
R.
Palencia,
P.
Kandaswamy,
L.
Li
(2014)
Cost-Effectiveness of Empagliflozin (Jardiance®) 10 Mg And 25 Mg Administered As An Add-on To Metformin Compared To Other Sodium-Glucose Co-Transporter 2 Inhibitors (Sglt2is) for Patients With Type 2 Diabetes Mellitus (T2dm) In The UK.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17 7
-
W.
Encinosa,
D.
Bernard,
A.
Dor
(2010)
Does Prescription Drug Adherence Reduce Hospitalizations and Costs?
Health Economics eJournal
-
R.
Turner,
R.
Holman,
I.
Stratton,
C.
Cull,
D.
Matthews,
S.
Manley,
V.
Frighi,
D.
Wright,
A.
Neil,
E.
Kohner,
H.
Mcelroy,
C.
Fox,
D.
Hadden,
Grp
Ukpds.
(1998)
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
The Lancet, 352
-
(1998)
UK Prospective Diabetes Study (UKPDS) group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).
, 352
-
(2010)
Does prescription drug adherence reduce hospitalizations and costs? The case of diabetes
, 22
-
Truven health. Wholesale acquisition cost [Internet]
-
S.
Mettam,
H.
Bajaj,
A.
Kansal,
P.
Kandaswamy
(2016)
Cost Effectiveness of Empagliflozin in Patients with T2DM and High CV Risk in Canada
Value in Health, 19
-
S.
Marso,
Gilbert
Daniels,
K.
Brown-Frandsen,
Peter
Kristensen,
Johannes
Mann,
Michael
Nauck,
Steven
Nissen,
Stuart
Pocock,
Neil
Poulter,
Lasse
Ravn,
William
Steinberg,
M.
Stockner,
B.
Zinman,
R.
Bergenstal,
J.
Buse
(2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
The New England journal of medicine, 375 4
-
C.
Tzanetakos,
Nicholas
Tentolouris,
Georgia
Kourlaba,
N.
Maniadakis
(2016)
Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece
Clinical Drug Investigation, 36
-
R.
Turner,
C.
Fox,
Matthews,
H.
Mcelroy,
C.
Cull,
R.
Holman,
P.
Neil,
D.
Hadden,
D.
Wright,
É.
Manley,
I.
Stratton,
Uk
Diabetes,
E.
Kohner,
Frighi,
Michael
Gnant
(1998)
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
The Lancet
-
A.
Garber,
M.
Abrahamson,
J.
Barzilay,
L.
Blonde,
Z.
Bloomgarden,
Michael
Bush,
S.
Dagogo-Jack,
R.
DeFronzo,
D.
Einhorn,
V.
Fonseca,
J.
Garber,
W.
Garvey,
G.
Grunberger,
Y.
Handelsman,
R.
Henry,
I.
Hirsch,
P.
Jellinger,
J.
McGill,
J.
Mechanick,
P.
Rosenblit,
G.
Umpierrez
(2016)
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 22 1
-
J.
Bekelman,
Yan
Li,
C.
Gross
(2003)
Scope and impact of financial conflicts of interest in biomedical research: a systematic review.
JAMA, 289 4
-
J.
Caro,
A.
Ward,
J.
O'brien
(2002)
Lifetime costs of complications resulting from type 2 diabetes in the U.S.
Diabetes care, 25 3
-
(2018)
American Diabetes Association. Introduction: standards of medical care in diabetes-2018
, 41
-
(2017)
National diabetes statistics report